Ken Fisher
CLDX icon

Ken Fisher’s Celldex Therapeutics CLDX Stock Holding History

Ken Fisher’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.2M Buy
1,013,648
+76,490
+8% +$2.09M 0.01% 279
2025
Q4 		$25.5M Buy
937,158
+10,001
+1% +$263K 0.01% 295
2025
Q3 		$24M Buy
927,157
+104,949
+13% +$2.43M 0.01% 301
2025
Q2 		$16.7M Sell
822,208
-49,420
-6% -$962K 0.01% 343
2025
Q1 		$15.8M Buy
871,628
+419,131
+93% +$9.36M 0.01% 353
2024
Q4 		$11.4M Buy
452,497
+78,145
+21% +$2.12M ﹤0.01% 416
2024
Q3 		$12.7M Buy
374,352
+253,808
+211% +$9.67M 0.01% 389
2024
Q2 		$4.46M Sell
120,544
-3,292
-3% -$124K ﹤0.01% 498
2024
Q1 		$5.2M Buy
123,836
+102,024
+468% +$4.19M ﹤0.01% 502
2023
Q4 		$865K Buy
21,812
+1,274
+6% +$37.5K ﹤0.01% 710
2023
Q3 		$565K Hold
20,538
– – ﹤0.01% 835
2023
Q2 		$697K Hold
20,538
– – ﹤0.01% 833
2023
Q1 		$739K Sell
20,538
-8,479
-29% -$366K ﹤0.01% 806
2022
Q4 		$1.29M Sell
29,017
-4,876
-14% -$174K ﹤0.01% 723
2022
Q3 		$953K Buy
+33,893
New +$1.04M ﹤0.01% 680

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Ken Fisher's CLDX Position: Q1 2026 in Review

Ken Fisher increased its Celldex Therapeutics (CLDX) stake by 8.2% in Q1 2026, buying an estimated $2.09M and bringing the position to 1,013,648 shares worth $32.2M. The position accounts for 0.01% of the portfolio, ranked #279.

Ken Fisher first reported a position in CLDX in Q3 2022 and has held it in 15 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Ken Fisher held 1,013,648 shares of Celldex Therapeutics worth $32.2M as of Q1 2026.
  • Ken Fisher bought 76,490 Celldex Therapeutics shares in Q1 2026, an estimated $2.09M.
  • Celldex Therapeutics made up 0.01% of Ken Fisher's portfolio in Q1 2026, its #279 holding.
  • Ken Fisher first reported a position in Celldex Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.